Pinpointing the Progression of Multiple Sclerosis - Differentiation, Evaluation and Treatment Updates
Once you're logged in, please select the "REGISTER" tab to process your payment and complete your registration.
Once you register for the course, you will have 180 days (approximately 6 months) from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
- Differentiate findings about the pathophysiology of Primary Progressive Multiple Sclerosis (PPMS).
- Identify specific aspects of evaluation, including objective tests and measures that can help to pinpoint PPMS and quantify its progression.
- Evaluate data on pharmacologic treatments that may emerge with a role in treating patients with PPMS.
Assessment of Need and References
Clinicians managing patients with PPMS are challenged by several aspects of this responsibility. Assessment can be confounded by patient perceptions and variable presentations and course, so effective evaluation must consider objective data such as MRI and assessment scale findings as well as the individual patient’s presentation and history. Treatment options have been limited to date and there is a lack of consensus on approach to treatment, so it is important that clinicians are able to analyze new data/treatment options expected to emerge, as a means of informing the selection of the safest and most effective options for care. View the entire assessment of need analysis and references.
- Clinical Gap 1: Differentiating and Evaluating: It is important that clinicians are equipped to accurately differentiate and evaluate PPMS (as compared with RRMS or secondary progressive MS [SPMS]), which affects a smaller percentage of patients but is also potentially much more disabling. In addition, acquiring foundational knowledge regarding pathophysiology can help to frame mechanisms of action for potentially effective treatments.
- Clinical Gap 2: Developments in Treatment: Due to the lack of approved effective treatments for PPMS thus far, clinicians must be informed about emerging agents that may offer some modification of the disease course.
Date of original release: December 8, 2017
Most recent review/update: December 8, 2017
Termination date: December 7, 2020
Robert T. Naismith, MD
Associate Professor of Neurology, Washington University School of Medicine in St. Louis
Relevant to the content of this CME activity, Dr. Naismith indicated he is a consultant for Acorda, Alkermes, Bayer, Biogen, EMD Serono, Genetech, Genzyme, Novartis, and Teva.
Kathy Mercuris, PT, DHS, C/NDT, CEEAA
Associate Professor in the Doctor of Physical Therapy Program, Des Moines University
Dr. Mercuris received her BS in Physical Therapy from Northwestern University and her Doctorate in Health Sciences at the University of Indianapolis. She is certified in adult hemiplegia by the Neurodevelopment Association, is a certified Tai Chi for Arthritis and Fall Prevention instructor, and has Certification as Exercise Expert in Aging Adults. She has 38 years of experience working with individuals with neurologic dysfunction and teaching in the Doctor of Physical Therapy Program at Des Moines University.
Relevant to the content of this CME activity, Dr. Mercuris indicated she has no financial relationships to disclose.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-B credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other: This enduring materials activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
This activity is supported by an educational grant from Genentech, Inc.
- 1.00 AMA PRA Category 1 Credits™
- 1.00 AOA Category 2B
- 1.00 CE Contact Hour(s)
- 1.00 IBON